Trinity Biotech shares have had a rough stretch—down sharply from their year high of $3.44 to trade near $0.77. The company just guided Q4 2025 revenue at $11.5M–$12.5M, a steep drop from $15.9M a year earlier. Yet some forecast models point to 310%+ upside, while analysts rate the stock “Reduce.” For anyone watching TRIB, the question is whether the bearish case is already priced in—or whether the risks still outweigh the potential.
Previous Close: $0.70 · Trade High: $0.75 · Trade Low: $0.68 · Year High: $3.44 · Volume: $116,404
Quick snapshot
- Q4 2025 guidance: $11.5M–$12.5M vs. $15.9M Q4 2024 (Stock Titan)
- Earnings release scheduled April 3, 2026 (Quiver Quantitative)
- Analyst consensus rating: “Reduce” (MarketBeat)
- Whether renewed Uni-Gold™ demand will hit 2026 revenue targets (Quiver Quantitative)
- How much the manufacturing outsourcing transition will affect H1 2026 stability (Stock Titan)
- Which algorithmic forecast model proves more accurate for TRIB (Stockscan.io)
- Q4 2024: $15.9M revenue reported
- Q4 2025: $11.5M–$12.5M guidance issued; 28% YoY decline
- April 3, 2026: Q4 2025 earnings release scheduled
- April 17, 2026: TRIB closed at $0.7454 after 6.58% gain
- Q4 2025 earnings on April 3, 2026 with analyst revenue estimate of $18.36M
- Uni-Gold™ HIV test outsourcing transition in progress
- HbA1c test expansion flagged as growth lever
The table below summarizes key trading data and identifiers for TRIB.
| Metric | Value |
|---|---|
| Exchange | NASDAQ |
| Ticker | TRIB |
| Previous Close | $0.70 |
| Year High | $3.44 |
| Recent Volume | $116,404 |
What is the stock price forecast for Trinity Biotech?
The 2026 forecast landscape for TRIB tells a jarring story: different platforms arrive at wildly different price targets. WalletInvestor, an algorithmic forecasting service, projects the stock falling to $0.6982 by April 2026 and dropping as low as $0.62958 by June 2026, with a potential trough around $0.519—representing a roughly 33% decline from recent levels. The platform’s last data pull showed TRIB trading near $0.77.
Stockscan.io, by contrast, paints a much brighter picture. Its models forecast an average 2026 price of $3.5676, with a bullish scenario reaching $6.0922 and a bear case floor of $1.043. The service’s 30-day forecast sits at $3.3112, implying over 320% upside from the $0.7818 baseline.
CoinCodex, which last updated its model on March 9, 2026, lands somewhere in between. Its end-of-2026 target range spans $0.6808 to $0.7560, with a trading channel between $0.7288 and $0.9711. ValueInvesting.io, drawing on 7-analyst consensus, takes the bullish view at an average 12-month target of $3.06, with a range of $3.03 to $3.15 and a BUY rating.
Forecasts diverge sharply: WalletInvestor and CoinCodex lean bearish ($0.63–$0.76), while Stockscan.io and ValueInvesting.io project $3.06–$3.57. Both sides claim models that predict direction—investors must weigh methodology credibility rather than pick the number they prefer.
TRIB Stock Forecast and Price Target 2026
For investors trying to find a single answer, the divergence itself is the signal. No single platform has demonstrated consistent accuracy for small-cap diagnostic stocks, and TRIB’s ongoing manufacturing transition introduces genuine uncertainty that pure algorithmic models may not capture well. WallStreetZen’s 2026 EPS forecast of -$0.50 (versus current EPS of -$1.50) suggests the company narrows its losses, but not to profitability.
Is Trinity Biotech a buy?
The analyst consensus from MarketBeat—based on 2 analysts—is a “Reduce” rating. That recommendation sits in tension with the upside potential some forecast models show. For investors weighing this, the case breaks down into two distinct arguments.
On the bearish side: Trinity Biotech’s revenue fell roughly 28% year-over-year in Q4 2025, dropping to $11.5M–$12.5M from $15.9M. The company attributes this decline to global HIV testing aid funding changes and disruptions from its manufacturing transition as it outsources HIV test production. The analyst consensus aligns with this caution—two analysts, one rating.
On the bullish side: the company’s Uni-Gold™ HIV tests face renewed demand in global markets, and HbA1c test expansion represents a potential growth lever. Regulatory approvals for outsourcing production have been secured, which could stabilize supply. If the strategic transition succeeds, the stock’s current level near $0.77—down from a year high of $3.44—could represent a reset that precedes recovery.
Upsides
- Uni-Gold™ HIV test demand renewal positions company for growth
- Current price near $0.77 offers significant discount from $3.44 year high
- HbA1c test expansion diversifies revenue beyond HIV testing
- Regulatory approvals for outsourcing remove production barriers
Downsides
- Revenue declined ~28% YoY in Q4 2025
- Manufacturing transition creates near-term revenue variability risk
- Analyst consensus is “Reduce” rating
- 2026 EPS forecast remains negative at -$0.50
- Forecasts diverge—bearish models see $0.63 or lower
The pattern: The analyst “Reduce” rating and bearish forecast models reflect caution about near-term execution risk, while the upside scenarios depend on successful transition execution that remains unproven.
What is the outlook for Trinity Biotech’s future growth?
Trinity Biotech specializes in human diagnostics and diabetes management, with Uni-Gold™ HIV tests as a core product line. The company’s Q4 2025 trading update—reported through Stock Titan—reveals a business in strategic transition. Revenue guidance of $11.5M–$12.5M for Q4 2025 reflects both headwinds from global HIV testing aid funding changes and disruption from shifting manufacturing to an outsourced model.
The company has secured key regulatory approvals for the outsourcing production model, which TipRanks notes as part of an accelerated growth plan. Quiver Quantitative’s coverage highlights renewed strength in global demand for Uni-Gold™ HIV tests, positioning the product as a potential revenue driver in 2026. However, the outsourcing transition may increase revenue variability through H1 2026 as the company manages the production handoff.
The gap between company guidance ($11.5M–$12.5M) and analyst revenue estimates ($18.36M) for Q4 2025 is substantial. Either the analysts are too optimistic, or the company is being conservative—which could mean upside surprises when actual earnings release on April 3, 2026.
Q4 2025 Trading Update
The April 3, 2026 earnings release will be the first public look at how Trinity Biotech navigated the revenue pressures outlined in its Q4 2025 guidance. Analyst estimates from Quiver Quantitative project revenue of $18.36M and EPS of -$0.17—a notably higher figure than the company’s own guidance range.
The implication: The divergence between company guidance and analyst estimates suggests either overly optimistic analyst projections or conservative company guidance—a resolution on April 3, 2026 will clarify which interpretation holds.
Key Business Developments
Beyond the top-line pressures, the company is simultaneously managing a product expansion (HbA1c tests) and a manufacturing transition. These are substantial operational changes being executed while revenue faces headwinds. For investors, the question is whether management can execute both transitions without further eroding the financial position.
What is Trinity biotech share price history?
TRIB’s trading range tells the story of a stock that has retraced sharply. The year high of $3.44 came during an earlier period of market optimism—likely before the full impact of HIV testing aid funding changes and manufacturing transition disruptions became apparent. The stock has since collapsed to the $0.68–$0.77 range, representing a decline of roughly 78% from peak.
Recent trading data shows TRIB at $0.7454 on April 17, 2026, after a 6.58% single-day gain. StockInvest.us predicted a fair opening price of $0.736 for April 21, 2026. The volume figure of $116,404 reflects relatively modest trading activity, consistent with a small-cap diagnostic company facing operational headwinds.
The pattern: The decline from $3.44 to below $0.80 tracks a multi-year retracement driven by revenue pressures and market sentiment shifts around the company’s operational challenges.
Historical price chart
The trajectory from $3.44 to below $0.80 represents a multi-year decline driven by revenue pressures and market sentiment. Investors who bought near the year high face substantial unrealized losses, while the current price level attracts those betting on either a turnaround or further decline.
Key milestones
The most significant recent milestone is the Q4 2025 guidance release, which framed the ~28% revenue decline and outlined the strategic response (outsourcing transition and product expansion). The April 3, 2026 earnings release will be the next major data point for investors tracking whether the strategic shifts translate to improved performance.
Who is the CEO of Trinity Biotech?
The research notes indicate Trinity Biotech’s leadership profile as relevant to investor decisions, though specific CEO details were not included in the verified facts available for this analysis. The company’s Q4 2025 trading update was issued publicly and covered by financial news sources including Quiver Quantitative, Stock Titan, and TipRanks.
For investors seeking detailed leadership information, the company’s official filings and investor relations materials would provide the most current and verified details on executive leadership and governance structure.
Leadership profile
Executive leadership can meaningfully impact strategic execution, particularly during periods of operational transition like the manufacturing shift Trinity Biotech is currently navigating. Investors should review the company’s investor relations materials for detailed information on executive experience and compensation.
Recent news
Beyond the Q4 2025 trading update, recent coverage includes TipRanks’ reporting on the manufacturing shift and growth plan acceleration, as well as coverage from financial analysis platforms tracking insider trading and hedge fund activity around the April 3, 2026 earnings release.
Timeline
- Trinity Biotech reported revenue of $15.9M (Stock Titan)
- Company issued trading update with $11.5M–$12.5M revenue guidance; ~28% YoY decline (Stock Titan)
- CoinCodex updated its TRIB price forecast (CoinCodex)
- Q4 2025 earnings expected before market open (Quiver Quantitative)
- TRIB closed at $0.7454 after 6.58% daily gain (Intellectia AI)
What analysts and the company are saying
Trinity Biotech guides Q4 2025 revenue to $11.5M–$12.5M, down from $15.9M. Global HIV testing aid funding changes reduced 2025 demand.
— Trinity Biotech (Company statement via Stock Titan)
Renewed strength in global demand for Uni-Gold™ HIV positions TRIB for 2026 revenue growth.
— Quiver Quantitative (Analysis via Quiver Quantitative)
The outsourcing transition may increase revenue variability in H1 2026 as the company manages the production handoff.
— Stock Titan (Financial news coverage via Stock Titan)
The divergence between company guidance and analyst estimates for Q4 2025 revenue—$11.5M–$12.5M versus $18.36M—merits close attention when earnings release on April 3, 2026. Either the company is being appropriately conservative about headwinds, or analysts are overestimating the recovery trajectory. The actual numbers will ground one side of this debate.
For investors watching TRIB, the decision framework is relatively clear: the stock trades at a fraction of its year high, some models show substantial upside potential if Uni-Gold™ recovery materializes, and the manufacturing transition—if successful—could stabilize supply and support revenue. Conversely, the analyst “Reduce” rating reflects genuine caution about near-term execution risk, and algorithmic forecasts that lean bearish cannot be dismissed outright.
Those willing to accept elevated volatility and uncertainty may find the risk-reward compelling at current levels. Those who prefer clear fundamental catalysts and analyst backing should wait for Q4 2025 earnings to provide concrete data before building a position.
Related reading: Symptoms of Lung Cancer: Early Signs and Warnings · Signs of Kidney Infection – Key Symptoms and When to Worry
walletinvestor.com, valueinvesting.io, moomoo.com, wallstreetzen.com
Biotech investors eyeing Trinity Biotech’s trajectory should note peers like Immunic, whose IMUX biotech outlook reflects pipeline-driven volatility.
Frequently asked questions
What factors affect Trinity Biotech share price?
TRIB’s price is driven by revenue performance from Uni-Gold™ HIV tests and HbA1c tests, progress on the manufacturing outsourcing transition, global HIV testing aid funding availability, and broader market sentiment toward small-cap diagnostic companies. Analyst ratings and algorithmic forecasts also influence investor positioning.
How has TRIB stock performed recently?
TRIB closed at $0.7454 on April 17, 2026, after a 6.58% single-day gain. The stock trades near $0.77 currently, significantly below its year high of $3.44. Recent volume has been modest at approximately $116,404.
What recent news impacts TRIB?
The Q4 2025 trading update released guidance of $11.5M–$12.5M revenue, down ~28% year-over-year from $15.9M. The April 3, 2026 earnings release will provide the next major data point. Analysts are tracking the manufacturing transition and Uni-Gold™ demand renewal.
Is there a Trinity Biotech stock split?
The research notes do not include information about a stock split for Trinity Biotech. Investors seeking split-related announcements should review the company’s official SEC filings and investor relations materials.
What are risks for TRIB investors?
Primary risks include continued revenue decline if HIV testing aid funding remains constrained, execution risk from the manufacturing transition, negative EPS trajectory (-$0.50 forecast for 2026), and analyst skepticism (MarketBeat consensus: “Reduce”). The stock also faces typical small-cap volatility and limited trading volume.
How to track Trinity Biotech share price?
TRIB trades on NASDAQ under the ticker TRIB. Real-time quotes are available through financial platforms including Yahoo Finance, Nasdaq, and MarketWatch. The April 3, 2026 earnings release will be a key upcoming catalyst.
What metrics matter for TRIB valuation?
Investors should monitor quarterly revenue growth, Uni-Gold™ HIV test sales volume, HbA1c test expansion progress, EPS trajectory, analyst rating changes, and the gap between company guidance and actual earnings. The manufacturing transition status and regulatory approval updates also provide signals on execution.